Uncategorized

Pharmazac participates in CPhI 2018.

Pharmazac launched the new product Abelfiz / aripiprazole 10, 15 and 30mg in hard tablets  for the treatment of schizophrenia in adults and in adolescents aged […]

Pharmazac launched the new product  Vasitimb / ezetimibe + simvastatin for theprevention of cardiovascular events, for hypercholesterlaemia and for theHomozygous Familial Hypercholesterolaemia. Therapeutic Indications Prevention of Cardiovascular Events Vasitimb is […]

Pharmazac was awarded the Salus Index 2016 Active Business Awards prize for its innovation in research and development of plant derived pharmaceutical products, pharmaceutical combinations and […]

Pharmazac launched the new product Apregalin® / pregabalin for the treatment of peripheral and central neuropathic pain in adults, for epilepsy as adjunctive therapy in adults […]

Pharmazac announces that its state-of-the-art Research and Development Lab at its headquarters received by the Greek Ministry of Health a GMP manufacturing license (clinical batches) for […]

Pharmazac is the official partner for Greece for the multinational companies Sintetica and Rokitan